This white paper summarizes a recent webinar convened by PRECISIONheor, moderated by Dr. Jeroen Jansen, Chief Scientist. The webinar featured a discussion surrounding the use of R for model-based cost-effectiveness analysis, and what can be done to increase its uptake and acceptance.
Following up from her last Insights90, Jacki Chou returns to explain 3 major changes in ICER’s recently released protocol for the 2022 national unsupported price increase assessment.
This month, PRECISIONheor highlights Director, Health Economics, Andrea Berardi.
Modern technology allows for the mass collection of digital health data. Artificial intelligence has become a vital tool for making sense of the huge volume of health data being collected daily through the use of big data analytics (BDA).
Last month, the FDA Office of Prescription Drug Promotion announced they will be conducting a discrete choice experiment study to understand how both patients and physicians weigh attributes of potential treatments.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
